Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andrew McConaghie

Advertisement
Set Alert for Articles By Andrew McConaghie

Latest From Andrew McConaghie

Gene Profiling Identifies Drugs For Childhood Cancers But Access A Problem

Lack of infrastructure for identifying mutations and access routes is holding back use of targeted medicines in children with cancer

Cancer Personalized Medicine

ESMO Preview: Five Key Oncology Battlegrounds To Watch

GSK looks to become a cancer contender once again, while Merck and Roche go toe-to-toe in TNBC.

Cancer Research & Development

Breakthrough Designation Confirms Gazyva Promise In Lupus Nephritis

Promising Phase II data mean it could be third time lucky for Roche in disease with no approved treatments. 

 

Commercial North America

Roche: We’ve Abandoned Budgets And It’s Liberated Employees

Bill Anderson says Roche has scrapped budgets and improved productivity and re-energised teams. But is it too good to be true?

Leadership Strategy

Bucking Biosimilar Threat, Roche Sees Further Growth

Many new and pipeline products were highlighted at London meeting – but no word on Spark Therapeutics deal. New products will have high profit margins.

Cancer Neurology

Investigating Big Pharma Licensing Trends

AstraZeneca emerged as big pharma’s most active dealmaker over the 2014-2018 period, thanks to a combined surge in both in-licensing and out-licensing agreements.

Deals Market Intelligence
See All
Advertisement
UsernamePublicRestriction

Register